Results 1 to 3 of about 5 (3)

Kouman Van Afekte Kay

EDIS, 2007
This is part of the Education + Action = Wind Damage Mitigation series by Kathleen C. Ruppert, Hal S. Knowles, and Karla A. Lenfesty that is now available in Spanish and Haitian Creole ABE379HAI/AE427: Kòman Van Afekte Kay yo (ufl.edu) Accessibility ...
Kathleen C. Ruppert, Hal S. Knowles, III, Karla A. Lenfesty   +2 more
doaj   +5 more sources

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors. [PDF]

Hum Vaccin Immunother, 2023
Hammitt LL, Quinn D, Janczewska E, Pasquel FJ, Tytus R, Reddy KR, Abarca K, Khaertynova IM, Dagan R, Dawson R, McCauley J, Shekar T, Fu W, Pedley A, Sterling T, Tamms G, Musey L, Buchwald UK.   +17 more
europepmc   +1 more source

Utility of Bulk T-Cell Receptor Repertoire Sequencing Analysis in Understanding Immune Responses to COVID-19. [PDF]

Diagnostics (Basel), 2022
Kockelbergh H, Evans S, Deng T, Clyne E, Kyriakidou A, Economou A, Luu Hoang KN, Woodmansey S, Foers A, Fowler A, Soilleux EJ.   +10 more
europepmc   +1 more source